Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 100 of 111 entries
View as:

Clinical Study to Evaluate the Efficacy and Safety of DA-2803 in Chronic Hepatitis B Patients

Phase: N/A Priority: Normal
NCT ID: NCT05957380 Org: User:
Start: 03/20/23 End: 09/30/24 Due: 09/30/25

A Therapeutic Exploratory Clinical Study of DA-8010 in Patients With Overactive Bladder

Phase: N/A Priority: Normal
NCT ID: NCT03566134 Org: User:
Start: 07/10/18 End: 12/27/19 Due: 12/27/20

Single-ascending Dose Phase 1 Clinical Trial to Evaluate the Safety and PK of DA-5207 TDS in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT04013477 Org: User:
Start: 06/18/19 End: 04/06/20 Due: 04/06/21

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of DA-8010 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02821312 Org: User:
Start: 06/30/16 End: 04/30/17 Due: 04/30/18

Study to Evaluate the Efficacy and Safety of Intra-articular DA-5202 in Patients With Osteoarthritis of the Knee

Phase: N/A Priority: Normal
NCT ID: NCT02554240 Org: User:
Start: 12/23/14 End: 10/14/16 Due: 10/14/17

Phase 1 Clinical Trial of DA-5207 in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT05127746 Org: User:
Start: 11/25/21 End: 12/13/22 Due: 12/13/23

PK//PD/Tolerability Study of DA-1229(Evogliptin) in Renal Impaired Patients

Phase: N/A Priority: Normal
NCT ID: NCT02214693 Org: User:
Start: 07/31/14 End: - Due: -

Phamacokinetics and Safety Profiles of DA-5210 10/500mg in Healthy Subjects at Fed State

Phase: N/A Priority: Normal
NCT ID: NCT05098275 Org: User:
Start: 10/26/21 End: 02/06/22 Due: 02/06/23

Study of Motilitone to Treat Functional Dyspepsia

Phase: N/A Priority: Normal
NCT ID: NCT02365701 Org: User:
Start: 06/30/15 End: 02/28/18 Due: 02/28/19

Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women

Phase: N/A Priority: Normal
NCT ID: NCT05630768 Org: User:
Start: 01/03/23 End: 07/31/25 Due: 07/31/26

Phase I Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of DA-7218 in Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02097043 Org: User:
Start: 05/31/14 End: 05/31/14 Due: 05/31/15

A Clinical Trial to Compare the Safety, Tolerability, and PK Properties of DA-5216 and DA-5216-R and to Evaluate the Food Effect on DA-5216.

Phase: N/A Priority: Normal
NCT ID: NCT05506007 Org: User:
Start: 08/29/22 End: 10/31/22 Due: 10/31/23

The Efficacy and Safety of OROSARTAN® Versus CODIOVAN® in Patients With Essential Hypertension Uncontrolled With Monotherapy

Phase: N/A Priority: Normal
NCT ID: NCT02433119 Org: User:
Start: 03/16/15 End: 09/08/16 Due: 09/08/17

Phamacokinetics and Safety Profiles of DA-5210 10/1000mg in Healthy Subjects at Fed State

Phase: N/A Priority: Normal
NCT ID: NCT05098886 Org: User:
Start: 11/07/21 End: 01/04/22 Due: 01/04/23

Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN)

Phase: N/A Priority: Normal
NCT ID: NCT02974504 Org: User:
Start: 09/30/16 End: 03/31/18 Due: 03/31/19

A Study to Demonstrate the Efficacy and Safety of Motilitone®

Phase: N/A Priority: Normal
NCT ID: NCT01817465 Org: User:
Start: 08/31/12 End: 03/31/14 Due: 03/31/15

Baracle Tab. ® Versus Baraclude Tab.® for Patients With HBeAg Chronic Hepatitis B

Phase: N/A Priority: Normal
NCT ID: NCT01913431 Org: User:
Start: 09/12/13 End: 11/06/15 Due: 11/06/16

Phase II Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia

Phase: N/A Priority: Normal
NCT ID: NCT01923545 Org: User:
Start: 07/31/10 End: 05/31/11 Due: 05/31/12

Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

Phase: N/A Priority: Normal
NCT ID: NCT04170998 Org: User:
Start: 01/02/20 End: 12/08/21 Due: 12/08/22

Efficacy and Safety of Evogliptin add-on to Metformin in Patients With type2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT02949193 Org: User:
Start: 05/31/13 End: 05/31/15 Due: 05/31/16

Phase I Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01162954 Org: User:
Start: 09/30/08 End: 03/31/09 Due: 03/31/10

Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

Phase: N/A Priority: Normal
NCT ID: NCT04356742 Org: User:
Start: 05/26/20 End: 02/23/22 Due: 02/23/23

Phamacokinetics and Safety Profiles of DA-1229_01 5/1000mg in Healthy Subjects at Fed State

Phase: N/A Priority: Normal
NCT ID: NCT05739916 Org: User:
Start: 03/30/23 End: 04/28/23 Due: 04/28/24

Pharmacokinetics & Safety Study of Clopidogrel 75mg and Aspirin 100mg Coadministration

Phase: N/A Priority: Normal
NCT ID: NCT01526122 Org: User:
Start: 09/30/11 End: 12/31/11 Due: 12/31/12

A Clinical Trial to Investigate Safety/Tolerability and Pharmacokinetics of DA-1229_01(Evogliptin/Metformin XR 2.5/500 mg x 2 Tablets) Compared to Co-administration of Evogliptin 5 mg and Metformin XR 1000 mg in Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02375139 Org: User:
Start: 04/30/15 End: 06/30/15 Due: 06/30/16